Efficacy

FOR PATIENTS WITH RELAPSED OR REFRACTORY AML
Single-agent fractionated MYLOTARG induced remission in difficult-to-treat patients in first relapse1,2
33% of patients achieved remission with single-agent MYLOTARG at Day 43
  • The efficacy of MYLOTARG was established on the basis of CR and duration of remission
Median overall survival (N=57)2
  • The median OS was 8.4 months
  • The study was stopped early when it met the prespecified endpoint, precluding the verification of OS data
AML=acute myeloid leukemia; CR=complete remission; CRp=CR with incomplete platelet recovery; mRFS=median relapse-free survival; ORR=overall response rate (CR + CRp); OS=overall survival. 
*Measured from the first documentation of CR or CRp to the date of relapse or death before relapse.2
REFERENCES
1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.
2. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66-71.